Pharmacokinetics of doxylamine given as bendectin® in the pregnant monkey and baboon

J. M. Rowland, W. Slikker, C. L. Holder, R. Denton, S. Prahalada, J. F. Young, Andrew G Hendrickx

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The object of the present study was to determine the maternal plasma pharmacokinetics of doxylamine (the antihistamine component of Bendectin®) following Bendectin® administration. Bendectin® was administered daily, po, at a dosage approximately 10 times the maximum human therapeutic dosage (7 mg/kg/day) throughout organogenesis (approximately days 22 through 50 of gestation) to three cynomolgus monkeys, four rhesus monkeys, and five baboons. Two pharmacokinetic experiments were performed in each animal, one on the first day of treatment and one on the last day of treatment. Although this study was not designed specifically as a teratologic examination, no morphologic abnormalities were observed when the fetuses were examined on approximately day 100 of gestation. A single-compartment, parallel first- and second-order elimination model was used to analyze the data. Although considerable interindividual variation was evident, no significant differences between species were observed when the half-life for the absorption of doxylamine from the gut or the elimination of doxylamine and metabolites from the plasma were compared. The plasma elimination half-lives and the clearance values were not altered by the 29 days of Bendectin® treatment for any of the species. Only the half-life for the absorption of doxylamine in the baboon was reduced by daily dosing with Bendectin®, but this did not alter doxylamine elimination. Thus, the pharmacokinetics of doxylamine administered as Bendectin® were similar in the three nonhuman primate species examined and were not altered by repeated daily administration.

Original languageEnglish (US)
Pages (from-to)197-202
Number of pages6
JournalReproductive Toxicology
Volume3
Issue number3
DOIs
StatePublished - 1989

Fingerprint

Doxylamine
Pharmacokinetics
Papio
Haplorhini
Plasmas
Half-Life
Pregnancy
Macaca fascicularis
Organogenesis
Histamine Antagonists
Metabolites
Macaca mulatta
Primates
dicyclomine, doxylamine, pyridoxine drug combination
Animals
Fetus
Mothers

Keywords

  • Baboon
  • Bendectin®
  • Development
  • Doxylamine
  • Monkey
  • Pharmacokinetics
  • Pregnancy

ASJC Scopus subject areas

  • Toxicology

Cite this

Rowland, J. M., Slikker, W., Holder, C. L., Denton, R., Prahalada, S., Young, J. F., & Hendrickx, A. G. (1989). Pharmacokinetics of doxylamine given as bendectin® in the pregnant monkey and baboon. Reproductive Toxicology, 3(3), 197-202. https://doi.org/10.1016/0890-6238(89)90007-5

Pharmacokinetics of doxylamine given as bendectin® in the pregnant monkey and baboon. / Rowland, J. M.; Slikker, W.; Holder, C. L.; Denton, R.; Prahalada, S.; Young, J. F.; Hendrickx, Andrew G.

In: Reproductive Toxicology, Vol. 3, No. 3, 1989, p. 197-202.

Research output: Contribution to journalArticle

Rowland, JM, Slikker, W, Holder, CL, Denton, R, Prahalada, S, Young, JF & Hendrickx, AG 1989, 'Pharmacokinetics of doxylamine given as bendectin® in the pregnant monkey and baboon', Reproductive Toxicology, vol. 3, no. 3, pp. 197-202. https://doi.org/10.1016/0890-6238(89)90007-5
Rowland, J. M. ; Slikker, W. ; Holder, C. L. ; Denton, R. ; Prahalada, S. ; Young, J. F. ; Hendrickx, Andrew G. / Pharmacokinetics of doxylamine given as bendectin® in the pregnant monkey and baboon. In: Reproductive Toxicology. 1989 ; Vol. 3, No. 3. pp. 197-202.
@article{0bf836417b664bcb8b1696e0cfe77945,
title = "Pharmacokinetics of doxylamine given as bendectin{\circledR} in the pregnant monkey and baboon",
abstract = "The object of the present study was to determine the maternal plasma pharmacokinetics of doxylamine (the antihistamine component of Bendectin{\circledR}) following Bendectin{\circledR} administration. Bendectin{\circledR} was administered daily, po, at a dosage approximately 10 times the maximum human therapeutic dosage (7 mg/kg/day) throughout organogenesis (approximately days 22 through 50 of gestation) to three cynomolgus monkeys, four rhesus monkeys, and five baboons. Two pharmacokinetic experiments were performed in each animal, one on the first day of treatment and one on the last day of treatment. Although this study was not designed specifically as a teratologic examination, no morphologic abnormalities were observed when the fetuses were examined on approximately day 100 of gestation. A single-compartment, parallel first- and second-order elimination model was used to analyze the data. Although considerable interindividual variation was evident, no significant differences between species were observed when the half-life for the absorption of doxylamine from the gut or the elimination of doxylamine and metabolites from the plasma were compared. The plasma elimination half-lives and the clearance values were not altered by the 29 days of Bendectin{\circledR} treatment for any of the species. Only the half-life for the absorption of doxylamine in the baboon was reduced by daily dosing with Bendectin{\circledR}, but this did not alter doxylamine elimination. Thus, the pharmacokinetics of doxylamine administered as Bendectin{\circledR} were similar in the three nonhuman primate species examined and were not altered by repeated daily administration.",
keywords = "Baboon, Bendectin{\circledR}, Development, Doxylamine, Monkey, Pharmacokinetics, Pregnancy",
author = "Rowland, {J. M.} and W. Slikker and Holder, {C. L.} and R. Denton and S. Prahalada and Young, {J. F.} and Hendrickx, {Andrew G}",
year = "1989",
doi = "10.1016/0890-6238(89)90007-5",
language = "English (US)",
volume = "3",
pages = "197--202",
journal = "Reproductigve Toxicoloy",
issn = "0890-6238",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Pharmacokinetics of doxylamine given as bendectin® in the pregnant monkey and baboon

AU - Rowland, J. M.

AU - Slikker, W.

AU - Holder, C. L.

AU - Denton, R.

AU - Prahalada, S.

AU - Young, J. F.

AU - Hendrickx, Andrew G

PY - 1989

Y1 - 1989

N2 - The object of the present study was to determine the maternal plasma pharmacokinetics of doxylamine (the antihistamine component of Bendectin®) following Bendectin® administration. Bendectin® was administered daily, po, at a dosage approximately 10 times the maximum human therapeutic dosage (7 mg/kg/day) throughout organogenesis (approximately days 22 through 50 of gestation) to three cynomolgus monkeys, four rhesus monkeys, and five baboons. Two pharmacokinetic experiments were performed in each animal, one on the first day of treatment and one on the last day of treatment. Although this study was not designed specifically as a teratologic examination, no morphologic abnormalities were observed when the fetuses were examined on approximately day 100 of gestation. A single-compartment, parallel first- and second-order elimination model was used to analyze the data. Although considerable interindividual variation was evident, no significant differences between species were observed when the half-life for the absorption of doxylamine from the gut or the elimination of doxylamine and metabolites from the plasma were compared. The plasma elimination half-lives and the clearance values were not altered by the 29 days of Bendectin® treatment for any of the species. Only the half-life for the absorption of doxylamine in the baboon was reduced by daily dosing with Bendectin®, but this did not alter doxylamine elimination. Thus, the pharmacokinetics of doxylamine administered as Bendectin® were similar in the three nonhuman primate species examined and were not altered by repeated daily administration.

AB - The object of the present study was to determine the maternal plasma pharmacokinetics of doxylamine (the antihistamine component of Bendectin®) following Bendectin® administration. Bendectin® was administered daily, po, at a dosage approximately 10 times the maximum human therapeutic dosage (7 mg/kg/day) throughout organogenesis (approximately days 22 through 50 of gestation) to three cynomolgus monkeys, four rhesus monkeys, and five baboons. Two pharmacokinetic experiments were performed in each animal, one on the first day of treatment and one on the last day of treatment. Although this study was not designed specifically as a teratologic examination, no morphologic abnormalities were observed when the fetuses were examined on approximately day 100 of gestation. A single-compartment, parallel first- and second-order elimination model was used to analyze the data. Although considerable interindividual variation was evident, no significant differences between species were observed when the half-life for the absorption of doxylamine from the gut or the elimination of doxylamine and metabolites from the plasma were compared. The plasma elimination half-lives and the clearance values were not altered by the 29 days of Bendectin® treatment for any of the species. Only the half-life for the absorption of doxylamine in the baboon was reduced by daily dosing with Bendectin®, but this did not alter doxylamine elimination. Thus, the pharmacokinetics of doxylamine administered as Bendectin® were similar in the three nonhuman primate species examined and were not altered by repeated daily administration.

KW - Baboon

KW - Bendectin®

KW - Development

KW - Doxylamine

KW - Monkey

KW - Pharmacokinetics

KW - Pregnancy

UR - http://www.scopus.com/inward/record.url?scp=0024773925&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024773925&partnerID=8YFLogxK

U2 - 10.1016/0890-6238(89)90007-5

DO - 10.1016/0890-6238(89)90007-5

M3 - Article

C2 - 2520523

AN - SCOPUS:0024773925

VL - 3

SP - 197

EP - 202

JO - Reproductigve Toxicoloy

JF - Reproductigve Toxicoloy

SN - 0890-6238

IS - 3

ER -